Advanced Search
KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 812-819. DOI: 10.3971/j.issn.1000-8578.2022.21.1323
Citation: KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 812-819. DOI: 10.3971/j.issn.1000-8578.2022.21.1323
shu

Advances in Treatment of Triple Negative Breast Cancer

  • Department of VIP Medical Services, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Funding: 

National Natural Science Foundation of China 81672634

National Natural Science Foundation of China 82172650

Beijing Medical Award Foundation YXJL-2020-0941-0763

Beijing Natural Science Foundation 7222150

More Information
  • Corresponding author:

    YUAN Peng, E-mail: yuanpengyp01@163.com

  • Received Date: November 14, 2021
  • Revised Date: February 03, 2022
  • Available Online: January 12, 2024
    Graphical Abstract
    • Abstract

  • TNBC is a special type of breast cancer with strong aggressiveness and poor prognosis. Chemotherapy is still the main treatment for TNBC, due to poor efficacy of endocrine therapy and targeted therapy. However, TNBC is a kind of heterogeneous disease, so it is urgent to study the precise molecular types and explore new precision treatment. This paper will summarize the results of clinical trials and analyze treatment strategies for TNBC, including surgical treatment, radiotherapy, chemotherapy, targeted therapy and immunotherapy, in order to provide evidence for clinical management.

    • FullText(HTML)

  • Competing interests: The authors declare that they have no competing interests.

    • References (52)
  • [1]
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. doi: 10.3322/caac.21590
    [2]
    Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
    [3]
    Torre LA, Islami F, Siegel RL, et al. Global Cancer in Women: Burden and Trends[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(4): 444-457. doi: 10.1158/1055-9965.EPI-16-0858
    [4]
    Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(15 Pt 1): 4429-4434.
    [5]
    Coughlin SS. Epidemiology of Breast Cancer in Women[J]. Adv Exp Med Biol, 2019, 1152: 9-29.
    [6]
    van Maaren MC, de Munck L, de Bock GH, et al. 10 year survival after breast-conserving surgery plus radiotherapy compared with mastectomy in early breast cancer in the Netherlands: a population-based study[J]. Lancet Oncol, 2016, 17(8): 1158-1170. doi: 10.1016/S1470-2045(16)30067-5
    [7]
    Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triplenegative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy[J]. J Clin Oncol, 2011, 29(21): 2852-2858. doi: 10.1200/JCO.2010.33.4714
    [8]
    Chen QX, Wang XX, Lin PY, et al. The different outcomes between breast-conserving surgery and mastectomy in triple-negative breast cancer: a population-based study from the SEER 18 database[J]. Oncotarget, 2017, 8(3): 4773-4780. doi: 10.18632/oncotarget.13976
    [9]
    Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer[J]. J Clin Oncol, 2006, 24(36): 5652-5657. doi: 10.1200/JCO.2006.06.5664
    [10]
    Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathologic parameters in stage Ⅱ/Ⅲ breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer[J]. BMC Cancer, 2007, 7: 203. doi: 10.1186/1471-2407-7-203
    [11]
    Untch M, Jackisch C, Schneeweiss A, et al. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): A randomised, phase 3 trial[J]. Lancet Oncol, 2016, 17(3): 345-356. doi: 10.1016/S1470-2045(15)00542-2
    [12]
    Gianni L, Mansutti M, Anton A, et al. Comparing Neoadjuvant Nabpaclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial[J]. JAMA Oncol, 2018, 4(3): 302-308. doi: 10.1001/jamaoncol.2017.4612
    [13]
    Sikov WM, Berry DA, Perou CM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: cALGB 40603 (Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21. doi: 10.1200/JCO.2014.57.0572
    [14]
    Zhang P, Yin Y, Mo H, et al. Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial[J]. Oncotarget, 2016, 7(37): 60647-60656. doi: 10.18632/oncotarget.10607
    [15]
    Alba E, Chacon JI, Lluch A, et al. A randomized phaseⅡ trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study[J]. Breast Cancer Res Treat, 2012, 136(2): 487-493. doi: 10.1007/s10549-012-2100-y
    [16]
    Byrski T, Huzarski T, Dent R, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients[J]. Breast Cancer Res Treat, 2014, 147(2): 401-405. doi: 10.1007/s10549-014-3100-x
    [17]
    Hahnen E, Lederer B, Hauke J, et al. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial[J]. JAMA Oncol, 2017, 3(10): 1378-1385. doi: 10.1001/jamaoncol.2017.1007
    [18]
    Mackey JR, Pieńkowski T, Crown J, et al. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial[J]. Ann Oncol, 2016, 27(6): 1041-1047. doi: 10.1093/annonc/mdw098
    [19]
    Wang X, Wang SS, Huang H, et al. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial[J]. JAMA, 2021, 325(1): 50-58. doi: 10.1001/jama.2020.23370
    [20]
    Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer[J]. N Engl J Med, 2021, 384(25): 2394-2405. doi: 10.1056/NEJMoa2105215
    [21]
    Isakoff SJ, Mayer EL, He L, et al. TBCRC009: A Multicenter PhaseⅡ Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer[J]. J Clin Oncol, 2015, 33(17): 1902-1909. doi: 10.1200/JCO.2014.57.6660
    [22]
    Yardley DA, Coleman R, Conte P, et al. nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial[J]. Ann Oncol, 2018, 29(8): 1763-1770. doi: 10.1093/annonc/mdy201
    [23]
    Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial[J]. Nat Med, 2018, 24(5): 628-637. doi: 10.1038/s41591-018-0009-7
    [24]
    Hu XC, Zhang J, Xu BH, et al. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Oncol, 2015, 16(4): 436-646. doi: 10.1016/S1470-2045(15)70064-1
    [25]
    Wang Z, Xu L, Wang H, et al. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment[J]. Saudi J Biol Sci, 2018, 25(5): 909-916. doi: 10.1016/j.sjbs.2018.01.011
    [26]
    Yuan P, Hu X, Sun T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial[J]. Eur J Cancer, 2019, 112: 57-65. doi: 10.1016/j.ejca.2019.02.002
    [27]
    Zhang P, Sun T, Zhang Q, et al. Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial[J]. Lancet Oncol, 2017, 18(3): 371-383. doi: 10.1016/S1470-2045(17)30088-8
    [28]
    Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation[J]. N Engl J Med, 2017, 377(6): 523-533. doi: 10.1056/NEJMoa1706450
    [29]
    Robson ME, Tung N, Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer[J]. Ann Oncol, 2019, 30(4): 558-566. doi: 10.1093/annonc/mdz012
    [30]
    Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer with a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8): 753-763. doi: 10.1056/NEJMoa1802905
    [31]
    O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer[J]. N Engl J Med, 2011, 364(3): 205-214. doi: 10.1056/NEJMoa1011418
    [32]
    O'Shaughnessy J, Sehwartzberg L, Danso MA, et al. Phase Ⅲ study of iniparib plus gemcitabine and carboplatin versus gemeitabine and carboplatin in patients with metastatic triple-negative breast cancer[J]. J Clin Oncol, 2014, 32(34): 3840-3847. doi: 10.1200/JCO.2014.55.2984
    [33]
    Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase Ⅰ/Ⅱ, single-arm, basket trial[J]. Ann Oncol, 2020, 31(12): 1709-1718. doi: 10.1016/j.annonc.2020.09.004
    [34]
    Son S, Shin S, Rao NV, et al. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy[J]. Int J Biol Macromol, 2018, 110: 406-415. doi: 10.1016/j.ijbiomac.2017.10.113
    [35]
    Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer[J]. N Engl J Med, 2021, 384(16): 1529-1541. doi: 10.1056/NEJMoa2028485
    [36]
    Nagayama A, Vidula N, Ellisen L, et al. Novel antibody-drug conjugates for triple negative breast cancer[J]. Ther Adv Med Oncol, 2020, 12: 1758835920915980.
    [37]
    Robert NJ, Die´ras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase Ⅲ trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer[J]. J Clin Oncol, 2011, 29(10): 1252-1260. doi: 10.1200/JCO.2010.28.0982
    [38]
    Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial[J]. Breast Cancer Res Treat, 2012, 133(3): 1067-1075. doi: 10.1007/s10549-012-2008-6
    [39]
    von Minckwitz G, Schneeweiss A, Loibl S, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial[J]. Lancet Oncol, 2014, 15(7): 747-756. doi: 10.1016/S1470-2045(14)70160-3
    [40]
    Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44)[J]. Ann Oncol, 2013, 24(12): 2978-2984. doi: 10.1093/annonc/mdt361
    [41]
    Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer[J]. N Engl J Med, 2012, 366(4): 310-320. doi: 10.1056/NEJMoa1111097
    [42]
    Lyons TG. Targeted Therapies for Triple-Negative Breast Cancer[J]. Curr Treat Options Oncol, 2019, 20(11): 82. doi: 10.1007/s11864-019-0682-x
    [43]
    Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase Ⅱ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 405-411. doi: 10.1093/annonc/mdy518
    [44]
    Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phaseⅡ KEYNOTE-086 study[J]. Ann Oncol, 2019, 30(3): 397-404. doi: 10.1093/annonc/mdy517
    [45]
    Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer[J]. N Engl J Med, 2018, 379(22): 2108-2121. doi: 10.1056/NEJMoa1809615
    [46]
    Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1): 44-59. doi: 10.1016/S1470-2045(19)30689-8
    [47]
    Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828. doi: 10.1016/S0140-6736(20)32531-9
    [48]
    Jiang YZ, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial[J]. Cell Res, 2021, 31(2): 178-186. doi: 10.1038/s41422-020-0375-9
    [49]
    Schmid P, Cortes J, Pusztai L, et al. KEYNOTE-522 Investigators. Pembrolizumab for Early Triple-Negative Breast Cancer[J]. N Engl J Med, 2020, 382(9): 810-821. doi: 10.1056/NEJMoa1910549
    [50]
    Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial[J]. Lancet, 2020, 396(10257): 1090-1100. doi: 10.1016/S0140-6736(20)31953-X
    [51]
    Nanda R, Liu MC, Yau C, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial[J]. JAMA Oncol, 2020, 6(5): 676-684. doi: 10.1001/jamaoncol.2019.6650
    [52]
    Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study[J]. Ann Oncol, 2022, 33(5): 534-543. doi: 10.1016/j.annonc.2022.02.004
    • Related Articles

  • Cited by

    Periodical cited type(7)

    1. 侯宁，孙光. RPS27a在三阴性乳腺癌中的作用及其潜在治疗策略. 中国实验诊断学. 2025(02): 220-223 .
    2. 程辰，王妍，赵红艳，于明，黄部发，李洪娥. 超声检查联合MRI预测TNBC及Ki-67表达水平的模型构建与评价. 医学影像学杂志. 2025(02): 68-73 .
    3. 邬欣悦，陈铭昱，徐力. 徐力从“虚”论治三阴性乳腺癌经验. 中医药临床杂志. 2024(03): 418-422 .
    4. 胡晓林，韩正祥. 三阴性乳腺癌患者雄激素受体、锌指蛋白44、p53蛋白表达特点. 北华大学学报(自然科学版). 2024(05): 626-631 .
    5. 高锦萍，郭燕鸿，王端端，陈燕青，刘羡琴. 乳腺癌决策辅助工具对乳腺癌患者决策冲突水平的影响研究. 当代护士(上旬刊). 2024(09): 85-90 .
    6. 史超，张香梅，刘运江. 三阴性乳腺癌免疫及靶向治疗研究进展. 肿瘤防治研究. 2023(07): 710-716 . 本站查看
    7. 艾勇彪，黄军，章书铭，李文仿. 三阴性乳腺癌新辅助化疗后肝功能异常的影响因素分析. 中国医药导报. 2023(26): 126-129 .

    Other cited types(10)

Catalog

    Tables(2)

    Get Citation
    PDF
    XML
    Article views (3637) PDF downloads (708) Cited by(17)
    Turn off MathJax
    Article Contents
    Abstract
    References

    Download Center

    Links

    Contact Us

    Address：116 Zhuodaoquan South Road,
    Hongshan District, Wuhan（430079）

    Tel：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits：18800176 Visits today：5967

    Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return